Company: CMND
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001213900-25-109567
Chunk: 14

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 14
---
 testing of our product candidates, working capital, future acquisitions and general capital expenditures. See “Use of Proceeds” on page S-15 of this prospectus supplement. |
| Risk factors                    |     | Investing in the Common Shares involves a high degree of risk. See “Risk Factors” beginning on page S-6 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of the risks you should carefully consider before deciding to invest in the Common Shares.                                    |
| Nasdaq Capital Market           |     | “CMND”                                                                                                                                                                                                                                                                                                                                                                                              |
| Frankfurt Stock Exchange symbol |     | “CSE”                                                                                                                                                                                                                                                                                                                                                                                               |

Unless otherwise stated, all information in this prospectus is based on 9,601,441 Common Shares outstanding as of November 12, 2025, and does not include the following as of that date:

| ● | 14,822,367 common shares issuable upon the exercise of warrants outstanding as of such date, at exercise prices ranging from $0.20 to $243.75, all of which were vested as of such date;                                                                                                    |
| ● | 5,521 common shares issuable upon the exercise of options to directors, employees and consultants under our incentive option plan outstanding as of such date, at a weighted average exercise price of $435.64, of which 5,513 were vested as of such date;                                 |
| ● | 76,251 common shares issuable upon the exercise of RSUs issued to consultants under consulting agreements; and                                                                                                                                                                              |
| ● | up to 12,835,241 common shares issuable upon the conversion of the Promissory Notes, calculated based on a principal amount of $2.5 million and the accrued interest thereon in the amount of $9,665 as of the date of this prospectus supplement and assuming a conversion price of $0.20. |

<div align='center'>S-5

RISK FACTORS</div>

Investing in our securities involves significant risks. Before making an investment decision, you should carefully consider the risks described below and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, together with all of the other information appearing in this prospectus supplement or the accompanying prospectus or incorporated by reference herein or therein, including in light of your particular investment objectives and financial circumstances. The risks so described are not the only risks we face. Additional risks not presently known to us